Why the study?
Does the presence of double genetic defects (factor V Leiden and G20210A prothrombin) increase the risk of recurrent DVT in patients following a first episode of DVT?
Does the presence of double genetic defects (factor V Leiden and G20210A prothrombin) increase the risk of recurrent DVT in patients following a first episode of DVT?
Answers are grounded in this paper and cite their sources.
Patients with a first DVT who lack proximal DVT and double genetic defects have a very low risk of recurrence (0.6% annual incidence), suggesting extended secondary thromboprophylaxis may not be necessary for this group.
The impact of the G20210A prothrombin mutation, factor V Leiden and 677T mutation of methylene tetrahydrofalate reductase (MTHFR) in recurrent deep venous thrombosis (DVT) is not so clear. We have prospectively monitored 259 patients following a first episode of DVT in order to determine which factors influence the development of a recurrent event. Several clinical and biological factors together with the genetic polymorphisms of factor V Leiden, G20210A prothrombin and 677T MTHFR were assessed. During a median follow-up of 786 patient-years, 27 patients (14%) developed one objective episode of recurrent venous thrombosis. The carriers of a double defect, homozygous or double heterozygous for factor V Leiden and G20210A, had an increased risk after a first episode of DVT, while patients who were isolated heterozygous for factor V Leiden or G20210 had a risk of recurrent DVT similar to patients who had neither mutation (annual incidence of 12.1, 3.1, 2.9 and 2.8%). The 677T MTHFR mutation alone or combined with hyperhomocysteinemia was not associated with an increased risk of recurrent events. The development of proximal DVT (P=0.01) and the presence of a double defect (P=0.01) were the only two risk factors independently associated with a high recurrence ratio in the multivariate analysis. Thus, the annual incidence of DVT recurrence in patients without any of these two risk factors was only 0.6% (95% confidence interval, 0.2-0.9). We have identified a group of patients with DVT but at very low risk of re-thrombosis in whom an extended secondary thromboprophylaxis should be carefully considered.
No takes yet. Share an insight, caveat, or question.
González‐Porras et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: